Use cases
Bladder PDO—not T24 / 5637 spheroids and not a full normal urothelial expansion course.
| Use | Fit | Readout | Notes |
|---|---|---|---|
| Cystectomy / biopsy PDO biobank + drugs | Recommended | Histology fidelity and drug vs clinical response[1] | Lee platform covers pre-/post-recurrence samples and interconverts with xenografts. |
| Normal urothelial contrast | Contrast | Toxicity / selectivity contrast | Keep normal and tumor dishes separate; do not mix drug plates. |
| T24 / 5637 spheroids as PDO | Do not mix | Spheroid diameter | Cell-line spheroids are not PDOs; in vivo uses transplant models. |
In one line
Bladder-tumor clusters → dome → urothelial niche → brief Y-27632 → mechanical split → CK/GATA3 → drugs.
Protocol overview
- Ethics + cold chain; log grade / stage, muscle invasion, and prior therapy
- Trim necrosis; collagenase ± Dispase to clusters; brief RBC lysis (MC427) if bloody
- Matrix domes; urothelial niche (EGF, FGF, Noggin, R-spondin ± Wnt, A83-01, nicotinamide…)[[1]]
- Brief Y-27632; score cystic vs solid growth
- Feed every 2–3 days; mechanical microcluster splits by growth
- CK7 / CK20, EpCAM, GATA3 if available; mycoplasma; match the primary
- Drugs with vehicle and standard arms; in vivo uses transplant SOPs (T24 / 5637…)—not this page